Autonomix Medical Takes Center Stage at Key Cardiology Conference
Autonomix Medical, Inc. (NASDAQ: AMIX) has gained attention for its pioneering work in precision nerve-targeted treatments. The company will present two significant studies at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Conference. This prestigious event, scheduled for October 25-28, will take place in San Francisco.
Highlighting Groundbreaking Research
The focus of these presentations revolves around an innovative approach to managing pain associated with pancreatic cancer, a condition that affects thousands and offers limited treatment options. Autonomix's first-in-human proof-of-concept clinical study explores the potential of transvascular energy to effectively ablate problematic nerves and alleviate pain in these patients.
Details on Presentations
The first presentation titled "Illuminating the Nervous System with Transvascular Precision-Guided Technology" will be delivered by Dr. Robert S. Schwartz, MD, FACC as part of the Innovation Session 7: Percutaneous Denervation for the Treatment of Chronic Diseases. This session is scheduled for Monday, October 27, at 7:30 AM PDT, located at the Innovation Theater, Hall E, Exhibition Level, Moscone North.
The second presentation, titled "Pain Mitigation in Pancreatic Adenocarcinoma: An Analysis of Denervation via Transvascular RF Energy-Based Ablation", will be conducted by the same presenter later that day at 9:00 AM PDT. This session will focus on Hypertension and Renal Denervation and will take place at Station 5, Halls B-C, Exhibition Level, Moscone South.
Understanding TCT 2025
The Transcatheter Cardiovascular Therapeutics conference is renowned for its role in advancing education and innovation in cardiovascular medicine. Founded by Dr. Martin B. Leon in 1988, TCT has evolved into a leading global forum for professionals in this field. Each year, it attracts thousands of professionals eager to share and learn about the latest breakthroughs in medical research.
Autonomix Medical's Vision
Autonomix aims to revolutionize the diagnosis and treatment of diseases involving the nervous system. Utilizing a first-in-class platform technology, the company has developed a catheter-based microchip sensing array. This sophisticated technology promises enhanced sensitivity in detecting neural signals, paving the way for improved diagnostic and therapeutic options.
Currently, the focus is on treating pain associated with pancreatic cancer—a debilitating condition that desperately needs innovative solutions. However, the platform's potential is broad, with implications for numerous conditions across various medical fields, including chronic pain management and cardiology. **It's essential to note that the technology is investigational and pending further evaluation before marketing clearance**.
Engaging with Autonomix Medical
At Autonomix, the commitment to advancing medical technology remains strong. The company continues to drive research aimed at transforming patient outcomes through innovative medical devices. The core mission revolves around not just treating symptoms but fundamentally changing how nervous system-related diseases are approached.
For anyone interested in the advancements being made by Autonomix, further information can be found on their official website or through their social media channels. Engaging with their content provides insights into their vision and progress, alongside updates on future innovations.
Frequently Asked Questions
What is the focus of Autonomix Medical, Inc.?
Autonomix Medical, Inc. is dedicated to developing precision nerve-targeted treatments to alleviate pain and improve patient outcomes in diseases involving the nervous system.
When is the TCT Annual Scientific Conference?
The TCT 2025 conference will be held from October 25-28, 2025, in San Francisco, California.
What kind of studies will Autonomix present at TCT 2025?
Autonomix will present results from studies focusing on using transvascular energy to address pain in pancreatic cancer patients.
Who will present the studies for Autonomix?
Dr. Robert S. Schwartz, MD, FACC, will deliver the presentations highlighting the company's innovative studies.
What does the future hold for Autonomix Medical technologies?
Autonomix plans to further develop its technologies across various indications, aiming to transform how diseases affecting the nervous system are diagnosed and treated.
